Vanguard Global Advisers’s Benitec Biopharma BNTC Stock Holding History
Bought
Maintained
Sold
Other funds holding BNTC
IAM
Vanguard Global Advisers's BNTC Position: Q3 2026 in Review
Vanguard Global Advisers increased its Benitec Biopharma (BNTC) stake by 48% in Q3 2026, buying an estimated $51.3K and bringing the position to 12,858 shares worth $129K. The position accounts for ﹤0.01% of the portfolio, ranked #2658.
Vanguard Global Advisers first reported a position in BNTC in Q1 2026 and has held it in 3 quarters since. 91 funds tracked by Wall St. Rank hold BNTC as of Q3 2026.
- Vanguard Global Advisers held 12,858 shares of Benitec Biopharma worth $129K as of Q3 2026.
- Vanguard Global Advisers bought 4,198 Benitec Biopharma shares in Q3 2026, an estimated $51.3K.
- Benitec Biopharma made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2658 holding.
- Vanguard Global Advisers first reported a position in Benitec Biopharma in Q1 2026 and has held it in 3 quarters since.
- 91 funds tracked by Wall St. Rank held Benitec Biopharma as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.